Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study.
Aged
Amoxicillin
/ administration & dosage
Anti-Bacterial Agents
/ administration & dosage
Atherosclerosis
/ blood
Cholesterol, HDL
/ blood
Clarithromycin
/ administration & dosage
Drug Therapy, Combination
/ methods
Female
Gastritis
/ blood
Helicobacter Infections
/ blood
Helicobacter pylori
/ drug effects
Humans
Lipid Metabolism
/ drug effects
Male
Middle Aged
Proton Pump Inhibitors
/ administration & dosage
Pyrroles
/ administration & dosage
Retrospective Studies
Sulfonamides
/ administration & dosage
Treatment Outcome
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
04
2019
accepted:
05
08
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
3
4
2020
Statut:
epublish
Résumé
Extra-gastric manifestation of Helicobacter pylori infection involves systemic inflammation, which results in the production of several cytokines. Only a few clinical trials have investigated the effect of H. pylori eradication therapy on lipid metabolism in the infected patients with chronic gastritis. We aimed to evaluate the effect of H. pylori eradication therapy on lipid metabolism in a Japanese population with chronic gastritis. One hundred and sixty-three patients with H. pylori-associated chronic gastritis were enrolled in this study between June 2015 and March 2017. They underwent H. pylori eradication therapy; the effects of the therapy were assessed by the urea breath test performed at least 4 weeks after the therapy. After confirming H. pylori eradication, the health screening examination was repeated between May 2016 and August 2018. The clinical parameters were compared before and after the administration of the eradication therapy. The mean age of the enrolled patients was 56.7 years, and the mean follow-up duration was 514.7 days. Weight, body mass index, and obesity index were significantly increased post-eradication therapy compared to those pre-eradication therapy. White blood cell and platelet counts were significantly decreased, and high density lipoprotein cholesterol (HDL) level was significantly increased (P = 0.001), while low density lipoprotein cholesterol (LDL), total cholesterol, and triglycerides levels were not altered significantly. Hence, the LDL/HDL ratio was significantly decreased. This study reported that H. pylori eradication therapy increase the HDL levels in the infected patients with chronic gastritis. Hence, the LDL/HDL ratio, which is used to evaluate the risk of atherosclerosis, was significantly decreased post-eradication therapy compared to that pre-eradication therapy.
Sections du résumé
BACKGROUND
Extra-gastric manifestation of Helicobacter pylori infection involves systemic inflammation, which results in the production of several cytokines. Only a few clinical trials have investigated the effect of H. pylori eradication therapy on lipid metabolism in the infected patients with chronic gastritis. We aimed to evaluate the effect of H. pylori eradication therapy on lipid metabolism in a Japanese population with chronic gastritis.
METHODS
One hundred and sixty-three patients with H. pylori-associated chronic gastritis were enrolled in this study between June 2015 and March 2017. They underwent H. pylori eradication therapy; the effects of the therapy were assessed by the urea breath test performed at least 4 weeks after the therapy. After confirming H. pylori eradication, the health screening examination was repeated between May 2016 and August 2018. The clinical parameters were compared before and after the administration of the eradication therapy.
RESULTS
The mean age of the enrolled patients was 56.7 years, and the mean follow-up duration was 514.7 days. Weight, body mass index, and obesity index were significantly increased post-eradication therapy compared to those pre-eradication therapy. White blood cell and platelet counts were significantly decreased, and high density lipoprotein cholesterol (HDL) level was significantly increased (P = 0.001), while low density lipoprotein cholesterol (LDL), total cholesterol, and triglycerides levels were not altered significantly. Hence, the LDL/HDL ratio was significantly decreased.
CONCLUSIONS
This study reported that H. pylori eradication therapy increase the HDL levels in the infected patients with chronic gastritis. Hence, the LDL/HDL ratio, which is used to evaluate the risk of atherosclerosis, was significantly decreased post-eradication therapy compared to that pre-eradication therapy.
Identifiants
pubmed: 31419266
doi: 10.1371/journal.pone.0221349
pii: PONE-D-19-09567
pmc: PMC6697333
doi:
Substances chimiques
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
0
Anti-Bacterial Agents
0
Cholesterol, HDL
0
Proton Pump Inhibitors
0
Pyrroles
0
Sulfonamides
0
Amoxicillin
804826J2HU
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221349Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Aliment Pharmacol Ther. 2002 Mar;16(3):577-86
pubmed: 11876713
Aliment Pharmacol Ther. 2002 Apr;16(4):799-806
pubmed: 11929399
Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:240-4
pubmed: 11966548
Hepatogastroenterology. 2002 Sep-Oct;49(47):1298-302
pubmed: 12239930
J Gastroenterol. 2003;38(4):339-47
pubmed: 12743773
Clin Biochem. 2003 Jul;36(5):359-65
pubmed: 12849867
Am J Cardiol. 2004 Jan 15;93(2):219-20
pubmed: 14715353
Antimicrob Agents Chemother. 1992 May;36(5):1133-5
pubmed: 1510406
Curr Opin Lipidol. 2004 Jun;15(3):269-78
pubmed: 15166782
J Gastroenterol. 2004 Jul;39(7):621-8
pubmed: 15293131
Dig Liver Dis. 2005 Jan;37(1):39-43
pubmed: 15702858
Dig Dis Sci. 2005 Jul;50(7):1228-31
pubmed: 16047464
J Am Coll Cardiol. 2005 Nov 15;46(10):1792-8
pubmed: 16286161
Dig Dis Sci. 2009 Mar;54(3):604-7
pubmed: 18649137
N Engl J Med. 1991 Oct 17;325(16):1127-31
pubmed: 1891020
Am J Gastroenterol. 2008 Dec;103(12):3005-10
pubmed: 19086952
J Atheroscler Thromb. 2010 Oct 27;17(10):1041-8
pubmed: 20610892
Atherosclerosis. 2011 Feb;214(2):442-7
pubmed: 21146820
Aliment Pharmacol Ther. 2011 Apr;33(8):922-9
pubmed: 21366634
J Korean Med Sci. 2011 May;26(5):654-8
pubmed: 21532857
J Atheroscler Thromb. 2013;20(5):452-64
pubmed: 23363982
J Gastroenterol. 2014 Jan;49(1):1-8
pubmed: 24162382
World J Gastroenterol. 2014 May 14;20(18):5226-34
pubmed: 24833852
World J Gastroenterol. 2014 Sep 28;20(36):12809-17
pubmed: 25278679
Helicobacter. 2015 Apr;20(2):125-32
pubmed: 25382033
Helicobacter. 2015 Jun;20(3):184-91
pubmed: 25582223
J Gastroenterol. 2015 Sep;50(9):996-1004
pubmed: 25622927
Sci Rep. 2016 Nov 28;6:38015
pubmed: 27892538
Circ J. 2017 Sep 25;81(10):1439-1446
pubmed: 28458377
Diabetes Metab Syndr. 2017 Dec;11 Suppl 2:S1031-S1035
pubmed: 28780229
J Clin Endocrinol Metab. 1989 Jan;68(1):191-9
pubmed: 2909551
Intern Med. 2018 Nov 1;57(21):3067-3073
pubmed: 29877271
J Clin Biochem Nutr. 2018 May;62(3):264-269
pubmed: 29892167
Medicine (Baltimore). 2018 Nov;97(46):e13271
pubmed: 30431613
Lancet. 1984 Jun 16;1(8390):1311-5
pubmed: 6145023
BMJ. 1995 Sep 16;311(7007):711-4
pubmed: 7549683
Gut. 1994 Nov;35(11):1567-70
pubmed: 7828974
N Engl J Med. 1993 Feb 4;328(5):349-50
pubmed: 8419823
Am J Gastroenterol. 1996 Jun;91(6):1150-6
pubmed: 8651162
Heart. 1996 Jun;75(6):573-5
pubmed: 8697159
Gastroenterology. 1997 Oct;113(4):1099-109
pubmed: 9322504
Atherosclerosis. 1999 Jan;142(1):207-10
pubmed: 9920523